Clinical trial
Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
NCT00322439 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00322439 |
|---|---|
| Title | Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis |
| Official title | Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Study type | Observational [Patient Registry] |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 2,511 |
| Start date | May 1, 2006 |
| Primary completion | Dec 11, 2012 |
| Completion | Feb 8, 2013 |
| First posted | May 8, 2006 |
| Last update posted | Jun 28, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: